A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide, produced and sold by Apothecary ...
Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in an all-cash, $1.3 billion deal that will boost its ...
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...
GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as a pre-operative treatment for rectal cancer that can eliminate ...
The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight management and treatment of type 2 diabetes (T2D). The decision puts ...
AstraZeneca has launched a project with tech giant Oracle that will use AI and real-world data to improve clinical research, ...
Researchers in the US have developed an AI foundation model – trained on millions of facial images – that seems to be able to ...
GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels, according to national newspaper L'Echo. The article notes ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Cecilia Caetano, vice president, global medical ...
In my experience, though, they are often used as a scapegoat for why social media doesn’t work in the pharma industry. I ...
Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors. The 19% after-market selloff came ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results